NK:IO raises more funding to advance pioneering NK cell therapy
NK:IO, a leader in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2 million (about US$1.5 million). This brings total equity financing to £3.2 million and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into […]
